Related Experiment Videos
[Clinicopathologic features of primary thyroid lymphoma]
Sheng-Yu Zhou1, Ding-Zhi Huang, Yuan-Kai Shi
1Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100-021, P.R. China.
AI Zheng = Aizheng = Chinese Journal of Cancer
|January 12, 2005
Summary
Primary thyroid lymphoma (PTL) is a rare B-cell malignancy, often misdiagnosed. Surgery-based combined modality is recommended for early-stage PTL (IE or IIE) for improved survival outcomes.
Area of Science:
- Oncology
- Hematology
- Pathology
Context:
- Primary thyroid lymphoma (PTL) is a rare endocrine malignancy.
- PTL is frequently misdiagnosed due to nonspecific symptoms.
- Treatment strategies for PTL remain a subject of debate.
Purpose:
- To investigate the clinicopathologic features of primary thyroid lymphoma.
- To explore optimal treatment modalities for PTL.
- To analyze survival outcomes in PTL patients.
Summary:
- This retrospective study analyzed 22 PTL patients (18 female, 4 male; median age 55).
- All cases were B-cell lymphomas, predominantly diffuse large B-cell lymphoma (DLBCL, 72.7%) and mucosa-associated lymphoid tissue (MALT) lymphoma (27.3%).
- Treatment approaches included surgery alone, surgery with radiotherapy, surgery with chemotherapy, or surgery with combined chemotherapy and radiotherapy. Five-year relapse-free survival was 34.78% and overall survival was 37.36%.
Impact:
- Highlights the predominance of B-cell origin in PTL, with DLBCL and MALT lymphoma as common subtypes.
- Suggests surgery-based combined modality treatment for early-stage PTL (Stage IE or IIE).
- Provides insights into survival rates, aiding in prognostic assessment and treatment planning for PTL.